2023
Impact and Implications of Neurocognitive Dysfunction in the Management of Ischemic Heart Failure
Tirziu D, Kołodziejczak M, Grubman D, Carrión C, Driskell L, Ahmad Y, Petrie M, Omerovic E, Redfors B, Fremes S, Browndyke J, Lansky A. Impact and Implications of Neurocognitive Dysfunction in the Management of Ischemic Heart Failure. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 101198. PMID: 39131066, PMCID: PMC11308118, DOI: 10.1016/j.jscai.2023.101198.Peer-Reviewed Original ResearchIschemic heart failureHeart failureNeurocognitive dysfunctionCognitive impairmentCoronary Artery Bypass GraftingArtery Bypass GraftingChronic cerebral hypoperfusionCoronary artery bypassPercutaneous coronary interventionPoor cognitive functionArtery bypassBypass GraftingCardiovascular outcomesCerebral hypoperfusionCoronary revascularizationCerebral hypoxiaCoronary interventionNeurologic injuryCardiac outputWorse outcomesBrain damageBrain injuryPatient outcomesInvasive approachPatient management
2020
Sex-Specific Outcomes in Cardiovascular Device Evaluations
Ghare MI, Tirziu D, Abbott JD, Altin E, Yang Y, Ng V, Grines C, Lansky A. Sex-Specific Outcomes in Cardiovascular Device Evaluations. Journal Of Women's Health 2020, 29: 1246-1255. PMID: 32543268, PMCID: PMC9545802, DOI: 10.1089/jwh.2019.8068.Peer-Reviewed Original ResearchConceptsCoronary revascularizationHeart failureClinical trialsDevice trialsMajor clinical trialsStructural heart diseaseSex-specific outcomesBenefit/risk assessmentCardiac resynchronization defibrillatorImplantable cardioverter defibrillatorVentricular assist deviceBest available careDrug eluting stentsBetter treatment recommendationsCardiovascular outcomesDevice therapyTreatment recommendationsHeart diseaseCardioverter defibrillatorDevice clinical trialsTreatment selectionAvailable careAssist deviceNarrative reviewEluting stents
2019
Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure
Pfau D, Thorn SL, Zhang J, Mikush N, Renaud JM, Klein R, deKemp RA, Wu X, Hu X, Sinusas AJ, Young LH, Tirziu D. Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure. Scientific Reports 2019, 9: 5791. PMID: 30962467, PMCID: PMC6453892, DOI: 10.1038/s41598-019-42113-0.Peer-Reviewed Original ResearchMeSH KeywordsAminobutyratesAngiotensin Receptor AntagonistsAnimalsBiphenyl CompoundsDrug CombinationsHeartHeart FailureMaleMyocardial Reperfusion InjuryMyocardiumNeovascularization, PhysiologicNeprilysinOrganotechnetium CompoundsPeptides, CyclicRatsRats, Inbred LewSingle Photon Emission Computed Tomography Computed TomographyTetrazolesValsartanVascular Endothelial Growth Factor AVentricular RemodelingConceptsSacubitril/valsartanExperimental heart failureHeart failureMyocardial infarctionMyocardial remodelingAngiotensin receptor neprilysin inhibitorAngiotensin receptor blocker valsartanMicroSPECT/CT imagingReceptor blocker valsartanHeart failure patientsProgressive LV dilationGlobal LV functionLV contractile dysfunctionNeprilysin inhibitor sacubitrilBorder zoneLimited remodelingFailure patientsInhibitor therapyMale LewisWeeks treatmentLV dilationLV functionNeprilysin inhibitorContractile dysfunctionInterstitial fibrosis